Q-omics provides the consensus-scored SYNJ2BP profile across patient tissues and cancer cell-line models. SYNJ2BP expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SYNJ2BP is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SYNJ2BP RNA expression shows 21,620 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where SYNJ2BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYNJ2BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYNJ2BP survival associations across molecular data types. SYNJ2BP RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYNJ2BP RNA expression–survival associations across cancer types. High SYNJ2BP expression shows unfavorable associations in HNSC, UVM, ACC and THCA, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SYNJ2BP RNA expression.
This table summarizes SYNJ2BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SYNJ2BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYNJ2BP shows lower tumor expression in KIRC, THCA, COAD, LUSC, LUAD and KIRP. The KIRC box plot shows higher SYNJ2BP RNA expression in normal versus tumor tissue (log2 FC = −1.335, t-test p < 0.001).
This table shows molecular features associated with SYNJ2BP in patient tissues and cancer cell lines. In patient samples, SYNJ2BP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SYNJ2BP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
